Noah Byrd

Prior to joining Cato BioVentures, Dr. Byrd was an NIH-funded postdoctoral fellow at Duke University Medical Center where he studied the genetic mechanisms underlying congenital heart defects utilizing Cre-loxP technology in mice.
Dr. Byrd has years’ research experience in the fields of angiogenesis and cardiovascular development, and his areas of expertise include vascular and cardiovascular disease, stem cell biology, neuronal differentiation, obesity, immunology, and medical devices.
He has over 10 years’ research experience in both academic and pharmaceutical settings.
Dr. Byrd graduated summa cum laude from the University of Tennessee and is a member of Phi Beta Kappa.
He is a member of the Regulatoy Affairs Professionals Society.